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Abstract
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FDA-approved BRAF inhibitors produce high response rates and improve overall survival in
patients with BRAF V600E/K mutant melanoma, but are linked to pathologies associated with
paradoxical ERK1/2 activation in wild-type BRAF cells. To overcome this limitation, a nextgeneration paradox breaking RAF inhibitor (PLX8394) has been designed. Here we show that by
using a quantitative reporter assay, PLX8394 rapidly suppressed ERK1/2 reporter activity and
growth of mutant BRAF melanoma xenografts. Ex vivo treatment of xenografts and use of a
patient-derived explant system (PDeX) revealed that PLX8394 suppressed ERK1/2 signaling and
elicited apoptosis more effectively than the FDA-approved BRAF inhibitor, vemurafenib.
Furthermore, PLX8394 was efficacious against vemurafenib-resistant BRAF splice-variant
expressing tumors and reduced splice-variant homodimerization. Importantly, PLX8394 did not
induce paradoxical activation of ERK1/2 in wild-type BRAF cell lines or PDeX. Continued in vivo
dosing of xenografts with PLX8394 led to the development of acquired resistance via ERK1/2
reactivation through heterogeneous mechanisms; however, resistant cells were found to have
differential sensitivity to ERK1/2 inhibitor. These findings highlight the efficacy of a paradoxbreaking selective BRAF inhibitor and the use of PDeX system to test efficacy of therapeutic
agents.
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INTRODUCTION
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Melanoma is the most aggressive form of cutaneous malignancy with a short time to
metastasis and high mortality rate. Enhanced MEK-ERK1/2 signaling occurs in most, if not
all, cutaneous melanomas and is frequently activated by a valine to glutamic acid mutation at
residue 600 (V600E) in the v-Raf murine sarcoma viral oncogene homolog B (BRAF)
protein (1). Recent targeted therapies have focused on selectively targeting BRAF V600E in
mutant BRAF-harboring melanomas. Selective BRAF inhibitors, vemurafenib (PLX4032)
and dabrafenib (GSK’436), have high response rates and provide remarkable improvements
in patients with mutant BRAF melanoma; however, the majority of patients develop
resistance within one year (2,3). In addition, a frequent side effect of vemurafenib and
dabrafenib is the induction of squamous cell carcinomas (SCCs) and keratoacanthomas
(KAs), which generally require surgical removal (4,5). While vemurafenib favors the V600E
form of BRAF (6), its binding to wild-type (WT) BRAF induces heterodimerization with
CRAF and ERK1/2 activation (7,8). This “paradoxical activation” of ERK1/2 likely
mediates vemurafenib induction of SCCs and KAs (4,5), leukemia (9,10) and mutant KRAS
pancreatic adenocarcinoma (11). Vertical targeting of the ERK1/2 pathway in melanoma
with BRAF plus MEK inhibitor combinations achieves a 64–76% response rate, extends
median progression free survival to over 9 months and reduces the adverse events associated
with paradoxical ERK1/2 activation (12–14). However, the BRAF plus MEK inhibitor
combination does not prevent relapse and can cause significant toxicities that may result in
treatment discontinuation (15). Checkpoint inhibitor agents, such as ipilimumab, nivolumab,
and pembrolizumab, act to relieve immunosuppressive signals and often elicit durable
responses; however they do not elicit response rates as high as targeted small molecule
inhibitors (11%–57.6% vs. 48%–69.6% respectively) (16). Furthermore, immunotherapy
approaches are generally not suitable for patients with bulky disease that require rapid
intervention (16), and an initial clinical trial combining vemurafenib with ipilimumab (a
CTLA-4 targeting agent) resulted in significant hepatotoxicity (17).

Author Manuscript

New targeted therapies that efficiently inhibit the ERK1/2 pathway with fewer and less
serious side effects would be clinically beneficial. Recently, next generation mutant BRAF
inhibitors have been designed that elicit strong efficacy in mutant BRAF melanoma cells but
do not elicit paradoxical ERK1/2 activation in mutant RAS-expressing keratinocytes (18–
24). Further examination of PLX8394 as a targeted agent is warranted as this agent enters
clinical trials since it may elicit fewer high grade toxicities than previous generations of
mutant selective BRAF inhibitors and the combination of BRAF plus MEK inhibitors.
Targeted inhibitors produce heterogeneous effects in mutant BRAF patients due to intrinsic
mechanisms of resistance and adaptive drug responses. There is an important need for
targeted agents to be tested in a personalized manner. Patient-derived xenograft models have
been developed but typically take several months to be propagated in mice (25–27). Here,
we describe the use of a patient-derived melanoma biopsy explant system (PDeX) and in
vivo ERK1/2 reporter models to show that PLX8394 is a potent BRAF inhibitor and does
not elicit paradoxical activation of ERK1/2 in vivo and ex vivo.
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MATERIALS AND METHODS
Ion Torrent sequencing
Vehicle treated and PLX8394 resistant tumors were harvested for genomic DNA with
Wizard Genomic DNA purification kit (Promega, Madison, WI). Samples were barcoded,
and sequenced using the Ion PGM 200 Sequencing Kit (Life Technologies). Full details see
Supplemental Data.
Western blot analysis
Western blot analysis was performed as in (28) with volumetric analysis in Quantity One
(Bio-Rad; Hercules, CA). Antibodies were purchased from Cell Signaling Technology
(Danvers, MA), Santa Cruz Biotechnology Inc., Biosciences Inc., Enzo (Farmingdale, NY),
and Sigma-Aldrich Co. (St. Louis, MO). Full details are in Supplemental Data.
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Inhibitors
Vemurafenib, dabrafenib, and trametinib (GSK’212) were purchased from Selleck
Chemicals LLC (Houston, TX). PLX8394, was provided by Dr. Gideon Bollag (Plexxikon
Inc., Berkeley, CA). PLX8394 for in vivo experiments was sent to Research Diets Inc. (New
Brunswick, NJ) for the production of chow.
Cell culture

Author Manuscript

1205LuTR GAL4-ELK1 reporter cells (Modified cell line – the parental was a gift from Dr.
Meenhard Herlyn (2005), PRT #3 (26), PBRT #15 and #16 cells (in vivo derived resistant
cells of 1205LuTR GAL4-ELK1 (2013)) were grown in MCDB 153 medium containing
20% Leibovitz-L15 medium, 2% FBS, 0.2% sodium bicarbonate, and 5 μg/mL insulin.
Additionally, PRT #3 cells were cultured in 1 μM PLX4720, and PBRT #15 and #16 cells
were cultured in 0.5 μM PLX8394. BOWES cells (Gift from Dr. Mark Bracke (2013)) were
grown in MEM containing 10% FBS, 1% non-essential amino acids, 1% sodium pyruvate,
and 1% HEPES buffer. B6, MeWo, (Gifts from Dr. Barbara Bedogni (2013)) and CHL-1
cells (Purchased from ATCC in 2013) were cultured in DMEM with 10% FBS. Pen/strep
(1%) was added to all media. All cells were grown at 37°C in a humidified incubator
supplemented with 5% CO2. Cells are routinely assayed for mycoplasma contamination with
MycoScope kit (Genlantis, San Diego, CA). Cells were assayed in April, May, and
September 2016. Cell line authentication via STR analysis was completed in April 2015 for
BOWES, MeWo, B6, and CHL-1, and in February 2017 for 1205LuTR GAL4-ELK1
reporter cells and PBRTs. B6 cells produced a unique profile, while all other cells matched
to known profiles.
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Immunohistochemistry
Tissue was fixed in formalin and paraffin embedded. Sections were stained for ERK1/2
phosphorylation (Thr202/Tyr204, #4370, Cell Signaling Technology), Staining was scored
using the digital Aperio ScanScope GL system in a blinded fashion by a pathologist (A.
Goldberg).
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Cells (1.4 × 104) were seeded in individual wells of 6-welled plates in regular culture
medium (containing 0.5 μM PLX8394 for PBRTs). The next day, plates were washed and
medium was replaced with medium supplemented with drugs of interest. Medium and drugs
were changed every 2 days. After 9 days, cells were fixed in buffered formalin with 0.2%
crystal violet. Plates were then scanned for quantitation via ImageJ.
Viability assays
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Cells (2 × 103) were seeded in triplicate in wells of a 96-welled plate in regular culture
medium (containing 0.5 μM PLX8394 for PBRTs). On the next day, cells were washed twice
with PBS and drug laced media added. After 4 days (including one medium change), 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent (Sigma-Aldrich Co.)
was added for 3 hours. Solubilized formazan was analyzed at 450 nM in a Multiskan
Spectrum spectrophotometer (Thermo Scientific, Chicago, IL). Results are normalized to
DMSO conditions and are a composite of three independent experiments.
Statistical analysis
Unless noted otherwise, significant values (indicated by an asterisk) were considered to have
a p value of ≤ 0.05 as determined by a two-tailed student’s T-test assuming unequal variance
and error bars are −/+ SEM. The effects of drug treatment on BRAF homodimers was
modeled by considering the treatment and experimental replicate (N=4) as predictors of
log(Myc/FLAG). ANOVA analysis was then performed with these considerations. IC50
calculations for ERK1/2 phosphorylation were performed using GraphPad Prism.

Author Manuscript

S-phase entry analysis
Cells (2.0 × 105) were seeded in 6-well plates. Cells were treated with drug of interest for 48
hours. The thymidine analog, EdU was added at a final concentration of 10 μMol/L for the
final 16 hours. EdU incorporation was measured using the Click-it EdU Alexa Flour 647
Flow Cytometry Assay Kit and was utilized as per manufacturer’s instructions (Molecular
Probes). EdU staining was quantified on BD FacsCalibur and data were analyzed with
FlowJo software. Data points are shown as averages of three experimental replicates.
Ex-vivo explant system

Author Manuscript

Tumors were collected following informed patient consent at Thomas Jefferson University
Hospital under an IRB-approved protocol (#10D.341). Less than 16 hours post-surgery,
excess adipose and stromal tissue was removed and tumors were cut into 1 mm3 pieces.
Vetspon absorbable hemostatic gelatin 1 cm3 sponges (Novartis; Basel, Switzerland) were
pre-soaked in 12-welled plates for 15 minutes at 37°C in 500 μL of DMEM/10% FBS
containing drugs or DMSO as a vehicle control. To avoid concerns of intratumoral
heterogeneity, up to three 1 mm3 pieces from different locations of the original tumor were
placed per sponge per treatment condition. Similarly, xenograft tumors were dissected into 1
mm3 pieces and placed on medium/drug-soaked sponges. Medium was replaced every 24
hours. Tumor pieces for western blotting were homogenized in modified RPPA lysis buffer
(29) with phosphatase and inhibitors (PhosSTOP and cOmplete tablets Roche, Basel,
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Switzerland). Laemmli sample buffer was added and samples were heated at ≥95°C for 5
minutes. For IHC analysis, tumor pieces were fixed in formalin for 24 hours. Two of the
samples (TJU-MEL-27A and TJU-MEL-27B) were different lesions from the same patient
and combo treatment was not assayed for TJU-MEL-30.
In vivo experiments

Author Manuscript

Seven-week old female nude mice (Jackson Laboratory, Bar Harbor, ME stock# 007850)
were injected with 1 × 106 1205LuTR GAL4-ELK1 reporter cells. Tumors were allowed to
form to ~100 mm3 at which point the mice were randomly divided into 2 cohorts and fed
either vehicle or PLX8394 laced chow. Tumor volumes and ERK1/2 reporter activity via
firefly luciferase measurements were recorded every 3–4 days. All mouse experiments were
performed at Thomas Jefferson University (Association for Assessment and Accreditation of
Laboratory Animal Care-accredited) and approved by the Institutional Animal Care and Use
Committee (IACUC). For full details see Supplemental Data.
Reverse Phase Protein Array (RPPA) analysis
1205LuTR GAL4-ELK1 parental reporter cells and PB-resistant tumor (PBRT) #15 and #16
cells (2.5 × 105/per condition) were seeded in 6-well plates in normal growth media
(containing 500 nM PLX8394 for PBRTs). The next day, cells were treated with either
DMSO or 0.5 μM PLX8394 for 24 hrs. Lysates from three independent experiments were
processed and analyzed as previously described (29), producing triplicates for each. For
analysis details see Supplemental Data section.
Immunoprecipitation assays
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1205LuTR cells expressing both Myc and FLAG tagged BRAF V600E ΔEx 2–8 were
seeded (1.0 × 106) on 10cm plates overnight. Cells were then dosed with 100 ng/mL
doxycycline to induce both splice variant expression for 48 hours. Plates were treated with
DMSO, PLX4720, or PLX8394 for an additional 4 hours. Cells were PBS washed, and lysed
in an NP40 based lysis buffer. 20 μL of pre-washed anti-FLAG Affinity Gel (#A2220
Sigma-Aldrich, Saint Louis, MO) was used to immunoprecipitate FLAG tagged target
during an overnight incubation at 4°C. The affinity gel was then washed 3× with cold TBS,
resuspended in Laemmli sample buffer and boiled for 5 minutes. Equal volume was loaded
on acrylamide gels for western analysis.

RESULTS
PLX8394 suppresses ERK1/2 signaling and tumor growth in vivo

Author Manuscript

PLX8394 is a mutant BRAF selective inhibitor, which potently blocks ERK1/2 signaling in
BRAF V600E/D-harboring melanoma cells in vitro (18,19,24). The structure of PLX8394
has been previously published (18). As an initial assessment of the cellular response to
PLX8394, we performed reverse phase protein array (RPPA) analysis on 1205LuTR GAL4ELK1 reporter cells (28) (Figure 1A). RPPA allows for quantitative assessment of >200
targets involved in growth factor signaling, cell cycle progression, apoptosis and histone
modification (29). In order to allow for cell cycle and apoptotic changes to take place, we
assayed samples at a 24 hour time point compared to an acute time point which would most
Mol Cancer Ther. Author manuscript; available in PMC 2019 January 01.
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likely only affect signaling. PLX8394 treatment significantly (p<0.05 and fold change ≥1.5)
altered 13 targets including down-regulation of phosphorylated MEK and ERK1/2, upregulation of the pro-apoptotic protein BIM, and down-regulation of cyclin B1 (Figure 1B).
We also observed up-regulation of the growth factor receptor, ERBB3, consistent with
previous findings with vemurafenib (30,31). Phosphorylation of Raf-1/CRAF and Src, which
are implicated in paradoxical ERK1/2 signaling and are suppressed by pan-RAF inhibitors,
remained unaffected by PLX8394 treatment (Supplemental Figure 1). To quantitatively
measure the effects of PLX8394 in vivo, we utilized xenografts from BRAF V600E
melanoma cells expressing an ERK1/2 luciferase-based reporter. This model permits
quantitative and temporal analysis in a non-invasive manner (28). ERK1/2 reporter luciferase
levels (adjusted for tumor volume) were significantly reduced within 7 days of PLX8394
treatment compared to vehicle controls (Figures 1C & 1D). PLX8394 also significantly
reduced tumor growth compared to vehicle-treated mice (Figure 1E). Together these results
show that PLX8394 inhibits ERK1/2 signaling in vitro, in vivo, and reduces tumor growth in
mutant BRAF melanoma xenografts.
PLX8394 suppresses phospho-ERK1/2 and elicits apoptotic markers in patient samples as
efficiently as combo treatment
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An ex vivo explant model has been previously utilized in prostate cancer (32,33). These
systems are advantageous for preclinical testing as they contain a stromal component and,
thus, more closely mimic the tumor microenvironment. We established and validated this
model in melanoma, using explants derived from xenograft tumors of 1205LuTR cells
(partially sensitive to PLX4720 - the tool compound for vemurafenib) and 1205LuTR-PRT
#3 cells which express a BRAF V600E splice variant and are resistant to PLX4720 (28,34).
Tumor tissue was treated ex vivo with vemurafenib at 1 μM, a standard concentration for in
vitro experiments (6,7,34) and 3D melanoma systems (35) or with 1 μM dabrafenib/16 nM
trametinib combination (combo) (Supplemental Figure 2A–2D). The dabrafenib and
trametinib combination at the given concentration is a clinically relevant molar ratio of the
two drugs that was found to have significant effect on downstream signaling (Supplemental
Figure 2F); this treatment served as a positive control for ERK1/2 pathway suppression to
demonstrate the range of response in the ex vivo explant system. These results provided
proof of concept for the Patient Derived eXplant (PDeX) system. Next, we extended PDeX
analysis to fresh human melanomas. Sequence-validated, mutant BRAF V600E melanoma
biopsy explants (Supplemental Figure 3A; Supplemental Table 1) were treated either with
vemurafenib, dabrafenib/trametinib combo, or PLX8394 for 48–72 hours. By
immunohistochemical staining of paraffin-embedded tumor sections and quantitative
analyses, vemurafenib inhibited ERK1/2 phosphorylation but inhibition was partial and
variable (Figure 2A & 2B). This observation is consistent with others who report a modest
response to vemurafenib in 3D tumor systems (35), and in stroma/melanoma co-culture
settings (36–38). By contrast, both combo and PLX8394 treatment consistently and
significantly inhibited ERK1/2 phosphorylation in PDeX (Figure 2A & 2B). By western blot
analysis, vemurafenib inhibition of ERK1/2 phosphorylation was again variable, but
statistically significant compared to vehicle treatment (Figure 2C & 2D; Supplemental
Figure 3C).
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Importantly, both PLX8394 and the dabrafenib/trametinib combination inhibited ERK1/2
phosphorylation by >60% (Figure 2B & 2D). Furthermore, PARP cleavage is associated
with ERK1/2 inhibition following combo and PLX8394 treatments (Figure 2C and
Supplemental Figure 3). To better understand pathway alterations, RPPA analysis was
performed on BRAF V600E human melanoma PDeX treated with targeted inhibitors.
Pathway analysis of the Programmed Cell Death/Apoptosis and Cell Cycle Arrest Gene
Ontology pathways by Gene Set Enrichment Analysis (GSEA) showed that vemurafenib
predominantly enriched a cell cycle arrest response, whereas PLX8394 and combo treatment
induced an apoptotic/cell death response (Figure 2E and Supplemental Figure 3F). In a
tumor with sufficient sample to assay the effects of a dose response to PLX8394, we
observed a dose dependent increase of PARP cleavage, as well as suppression of ERK1/2
phosphorylation. RPPA analysis of this sample demonstrated a dose dependent decrease of
ERK1/2 pathway targets, and increase in the pro-apoptotic protein BIM (Supplemental
Figure 3D and 3E). Taken together, these data suggest that PLX8394 is a potent inhibitor of
ERK1/2 phosphorylation in human BRAF V600E melanomas and elicits effects comparable
to the current FDA-approved dabrafenib/trametinib combination in an explant model.
PLX8394 is more potent in suppressing ERK1/2 phosphorylation than vemurafenib and is
efficacious against constitutively dimerized BRAF splice variants

Author Manuscript
Author Manuscript

To determine the efficacy of PLX8394 compared to vemurafenib in the explant system,
xenografts were generated with 1205LuTR GAL4-ELK1 parental cells and two different in
vivo derived RAF inhibitor resistant lines, PRT #3 and PRT #4 (28). Xenografts tumors were
excised and used in the explant system to assay dose responses. After 48 hours of treatment,
western blotting was used to measure ERK1/2 phosphorylation and PARP cleavage. We
found that PLX8394 more efficiently suppressed ERK1/2 phosphorylation (IC50 0.01 uM
vs. 1.39 uM) and elicited PARP cleavage compared to vemurafenib in parental 1205LuTR
(Figure 3A, and Supplemental Figure 4A). Importantly, while vemurafenib treatment was
largely ineffective (ERK1/2 phosphorylation IC50 is undefined for PRT #3 and 4.05 mM for
PRT #4), PLX8394 inhibited ERK1/2 phosphorylation (0.97 μM and 0.096 μM for PRT #3
and #4, respectively) and induced PARP cleavage in BRAF splice-variant expressing tumors,
PRT #3 and PRT #4 (Figure 3B, 3C & Supplemental Figure 4B, 4C). It is noteworthy that
while the PRT tumors were sensitive to PLX8394, both required a higher dose of PLX8394
than parental cells to suppress ERK1/2 phosphorylation. This result is consistent with other
RAF inhibitor-resistant cells treated with potential second-line RAS-RAF-MEK-ERK
pathway targeting agents (34,39). Since constitutive BRAF splice variant homodimerization
has been linked to vemurafenib resistance (39), we investigated if PLX8394 affects
homodimerization of BRAF splice variants. 1205Lu cell lines were created to inducibly coexpress both Myc-tagged and FLAG-tagged versions of BRAF splice variants lacking exons
two through eight (1205LuTR FLAG/Myc BRAF ΔEx 2-8). BRAF ΔEx 2-8 is equivalent to
the BRAF splice variant expressed in PRT #4. Similar to the PRT tumors, this cell line
demonstrated a dose dependent reduction of ERK1/2 pathway signaling from PLX8394 but
not PLX4720 treatment (Figure 3D). Parallel lysates were then used to query
homodimerization by immunoprecipitation of the FLAG-tagged BRAF splice variant and
probing for the association of its Myc-tagged binding partner. While both drugs impaired
homodimerization, PLX8394 treatment elicited a more profound reduction than PLX4720
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(Figure 3E and 3F). Interestingly, PLX8394 dosing had little effect on homodimerization
status (Supplemental Figure 4D), yet higher doses of PLX8394 were able to inhibit MEK
phosphorylation. These observations suggest that while PLX8394 blocks dimerization and
ERK1/2 pathway more efficiently than PLX4720, the extent of BRAF splice variant
homodimerization itself may not be wholly responsible for vemurafenib resistance.
Together, these data demonstrate superior efficacy of PLX8394 as a single agent RAF
inhibitor in comparison to vemurafenib and that PLX8394 can overcome mutant BRAF
splice variants, a common mechanism of BRAF inhibitor resistance.
PLX8394 attenuates the paradoxical ERK1/2 activation in WT/WT melanoma tissue
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An important goal in the design of PLX8394 is to reduce hyper-activation of ERK1/2 in WT
BRAF-containing tissues. To demonstrate the “paradox breaking” ability of PLX8394, we
treated WT BRAF/WT NRAS (WT/WT) melanoma cell lines with vemurafenib, PLX8394
and trametinib in 2D culture conditions. Vemurafenib significantly increased ERK1/2
signaling in CHL-1, BOWES, MeWo, and B6 WT/WT melanoma cell lines compared to
DMSO control (Figures 4A & 4B). In contrast, PLX8394 treatment did not produce a
statistically significant increase in paradoxical activation and treatment with trametinib
strongly reduced ERK1/2 phosphorylation. Extending these studies into explants derived
from xenografts from the WT/WT BOWES and B6 cells, vemurafenib enhanced ERK1/2
activation in WT/WT xenograft explants similar to experiments in 2D (Figure 4C). In
comparison to vemurafenib, PLX8394 did not induce strong paradoxical ERK1/2 activation
in these samples. Furthermore, we tested paradoxical activation by RAF inhibitors using the
PDeX system in a WT/WT patient sample (Supplemental Figure 3B). Western blot analysis
demonstrated a strong paradoxical phosphorylation of ERK1/2 induced by vemurafenib, but
comparatively weak ERK1/2 phosphorylation in response to PLX8394 (Figure 4D). As
expected, the MEK inhibitor trametinib suppressed ERK1/2 signaling (Figure 4D). Taken
together, these data show that when using doses effective in suppressing ERK1/2 signaling
in mutant BRAF tumor, PLX8394 does not elicit strong paradoxical signaling in WT BRAF
tissue, representing an improvement over the previous generation of BRAF inhibitors.
Acquired resistance to PLX8394 is associated with ERK1/2 reactivation and deregulation
of ERK1/2-independent pathways
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Treatment with targeted therapies is invariably associated with acquired resistance;
therefore, we investigated the duration of PLX8394 effects on BRAF V600E melanomas in
vivo. Mice bearing mutant BRAF xenografts were continued on PLX8394 treatment until
progression (≥1000mm3 tumor size or displayed signs of ulceration). Progressing tumors
were excised and two Paradox Breaker Resistant Tumor (PBRT) cell lines, #15 and #16
were propagated. PBRT #15 and PBRT #16 were isolated at day 45 and 35 post drug
treatment, respectively. In 2D colony formation assays, PLX8394 suppressed the growth of
1205LuTR parental cells in a dose dependent manner (Figure 5A & 5B). Conversely, PBRT
#15 maintained growth in PLX8394 and PBRT #16 exhibited addiction to PLX8394, similar
to a phenomenon observed in vemurafenib-resistant cells (34). In MTT assays, PLX8394
potently inhibited the viability of parental cells but both PBRT #15 and #16 cell lines were
highly resistant to the inhibitor (Supplemental Figure 5A).
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To understand pathway alterations associated with resistance to PLX8394, we performed
RPPA analysis on PBRT #15 and #16 compared to parental 1205LuTR cells. Compared to
parental 1205LuTR cells, the levels of 34 proteins significantly changed (1.5 fold; p≤ 0.01)
in either the DMSO control or PLX8394 conditions (Figure 5C). Western blotting confirmed
the RPPA results showing maintenance of ERK1/2 phosphorylation in PBRT #15 and #16
cells treated with PLX8394 (Supplemental Figure 5B & 5C). Additionally, PBRT cells
treated with PLX8394 exhibited significantly higher levels of Rb phosphorylation than
PLX8394-treated parental cells (Supplemental Figure 5D), reflecting the ability of PBRT
cells to overcome PLX8394-mediated cell cycle inhibition. Interestingly, both PBRT cell
lines displayed increased AKT phosphorylation, enhanced PDGFR levels and reduced βcatenin expression compared to 1205LuTR parental cells (Supplemental Figure 5B and 5E–
G). These alterations have been previously implicated in resistance to vemurafenib (40–44),
but did not appear to be primary drivers of resistance in the PBRTs (Supplemental Figure 6).
Furthermore, BRAF V600E splice variants, which drive resistance to vemurafenib, were not
detected in PBRT cell lines (Supplemental Figure 7A). Thus, as with other RAF inhibitors
and MEK-ERK1/2 regimens, prolonged exposure to PLX8394 results in acquired resistance
associated with ERK1/2 pathway re-activation and compensatory pathway alterations.
PBRT cell lines have differential sensitivities to ERK1/2 pathway inhibition
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We tested whether vertical targeting of the ERK1/2 pathway would overcome the acquired
resistance to PLX8394, as it does in other resistant melanoma models (27,39). Individual
treatments of PLX8394, vemurafenib, trametinib, and the ERK1/2 inhibitor SCH772984
(SCH772) suppressed ERK1/2 signaling and reduced Rb phosphorylation in parental cells
(Figure 6A). While trametinib reduced phospho-ERK1/2 in both PBRT #15 and #16, Rb
phosphorylation was only affected in PBRT #15 (Figure 6A). Similarly, SCH772 treatment
reduced Rb phosphorylation in PBRT #15 but not PBRT #16 (Figure 6A). Dose escalation of
SCH772 was associated with an increase in PARP cleavage and BIM levels, as well as a
reduction of both Rb phosphorylation and cyclin A expression in PBRT #15 (Supplemental
Figure 7B). However, these changes were not observed in PBRT #16 (Supplemental Figure
7B). Similarly, crystal violet growth and EdU incorporation assays demonstrated that both
parental and PBRT #15 cell lines were more sensitive to ERK1/2 inhibitor treatment than
PBRT #16 (Figure 6B–6C and Supplemental Figure 7C).
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Ion torrent sequencing results of PBRT #15 and PBRT #16 did not yield any missense
mutations that would be indicative of ERK1/2 inhibitor resistance (Supplemental Tables 2
and 3). Consequently, we postulated that transcriptional alterations may contribute to
resistance. Therefore, we utilized epigenetic agents, the bromodomain and extra-terminal
domain (BET) bromodomain (BRD) inhibitor, JQ1. Western blot analysis demonstrated that
JQ1 treatment increased levels of the cyclin-dependent kinase inhibitors, p21 and p27, in
PBRT #16 (Figure 6D). This correlated with increased sensitivity of PBRT #16 to BET/BRD
inhibitors in crystal violet growth assays and EdU incorporation (Figure 6E–6F and
Supplemental Figure 7D). While PBRT #16 was more sensitive to BET/BRD inhibitor
treatment, these agents also suppressed growth of PBRT #15 suggesting a potential universal
second-line therapy option (Figure 6E and Supplemental Figure 7D).
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DISCUSSION
FDA-approved mutant BRAF selective inhibitors have markedly improved the treatment
options and outcomes for BRAF V600E/K melanoma patients but are limited by the
occurrence of adverse events associated with paradoxical ERK1/2 activation. In this study,
we show the efficacy of the next-generation “paradox breaking” BRAF inhibitor, PLX8394.
Overall, our data support that PLX8394 is a viable treatment option to efficiently inhibit
ERK1/2 signaling while limiting paradoxical effects in WT BRAF cells and highlight the
use of tumor explants to rapidly assess the utility of targeted agents.

Author Manuscript

Using an in vivo GAL4-ELK1 reporter system to quantitatively and temporally measure
ERK1/2 signaling in melanoma xenografts (28), we show that PLX8394 effectively inhibits
ERK1/2 signaling and reduces mutant BRAF melanoma growth. This approach is
complemented by an ex vivo explant system that demonstrates PLX8394 effectively inhibits
ERK1/2 phosphorylation in patient tumors. Vemurafenib treatment only elicited a ~20%
reduction in ERK1/2 phosphorylation in explants consistent with others’ observations of
minimal vemurafenib efficacy in 3D tumor mimics (35), and stroma/melanoma co-culture
systems (36–38). Variability in the response of patient tumors to vemurafenib may also be
due to different treatment histories of the patients (Supplemental Table 1) and/or a high
stromal component, which displays paradoxical ERK1/2 activation (35). By contrast,
PLX8394 consistently inhibited ERK1/2 signaling in all patient biopsies independent of
treatment history, and was comparable to dabrafenib/trametinib combination therapy.

Author Manuscript

PLX8394 demonstrated enhanced efficacy when directly compared to vemurafenib in
parallel ex vivo dosing of xenograft tissue. This may not be surprising as the PLX8394 IC50
for ERK1/2 phosphorylation is ~10 fold lower than vemurafenib (18). By contrast, in the
explant system, the dose required to reach ERK1/2 phosphorylation IC50 of parental mutant
BRAF tumor tissue treated with vemurafenib was much higher (~44x IC50) compared to
PLX8394 (~3x IC50) (Figure 3A). One explanation for the larger difference of vemurafenib
effectiveness is the potential paradoxical activation of ERK1/2 signaling in the stromal
component present in the explant tissue which is not present in 2D culture systems.
Vemurafenib has been shown to paradoxically elicit tumor protective responses from stromal
components in ex vivo systems, as well as stimulate production of mitogenic growth factors
from wild type BRAF tumors in vivo (18,35), a phenomenon that should be attenuated in
PLX8394 treatment. The moderate increase in ERK1/2 phosphorylation IC50 for PLX8394
treatment in the explant system, compared to 2D culture, may reflect ERK1/2 signaling
present in stromal cells that should not be inhibited or paradoxically activated.

Author Manuscript

PLX8394 was effective in suppressing ERK1/2 signaling and eliciting PARP cleavage in
BRAF splice variant-expressing, vemurafenib-resistant samples. This may be in part due to
PLX8394’s ability to better suppress splice variant homodimerization, thereby facilitating
efficient inhibition of monomeric mutant BRAF kinase. Homodimerization of mutant BRAF
splice variant expressing cells has been linked to RAF inhibitor resistance (28,39); however,
the dimerization status of these splice variants in the presence of RAF inhibitors has not
been tested. Vemurafenib and PLX4720 have previously been shown to destabilize
homodimerization of full length mutant BRAF (45) and heterodimerization of wild-type
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BRAF kinase domain with CRAF (46). On the other hand, reports indicate that these drugs
may enhance BRAF/CRAF heterodimers (23). In the present study, we utilize differentially
tagged V600E BRAF splice variants to measure homodimerization status during drug
treatment to model the setting in which splice variants are expressed. We found that while
both PLX4720 and PLX8394 reduced homodimerization of V600E BRAF splice variants,
PLX8394 was significantly more effective. It is possible that the residual dimerized splice
variant in PLX4720 treated cells may be adequate for drug resistance as further blocking of
homodimerization by PLX8394 is associated with ERK1/2 pathway inhibition.
Alternatively, these data may indicate that although splice variant homodimerization
contributes to signaling in the presence of vemurafenib, it may not be wholly responsible for
RAF inhibitor resistance.
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The explant system was also used to show that vemurafenib, but not PLX8394, induces a
strong paradoxical activation of ERK1/2 in WT/WT melanoma. Other groups have reported
on pan-RAF/Src inhibitors that do not elicit paradoxical activation properties (47); however,
the mutant BRAF selectivity of PLX8394 may afford a higher therapeutic index than agents
that broadly inhibit RAF kinases. Furthermore, the mutant BRAF specific targeting
properties of PLX8394 may enable its use in combinatorial regimens with immune
therapies. Since suppression of ERK1/2 signaling is associated with increased melanoma
antigen presentation (48), it is advantageous to use targeted inhibitors as an adjuvant to
improve immunotherapy efficacy. However, there are conflicting reports of how systemic
pathway inhibition (i.e. MEK inhibitor treatment) affects the anti-tumor immune response
(49–51). Our results indicate that at doses that would inhibit mutant BRAF tumors,
PLX8394 minimally affects ERK1/2 status in WT/WT cells, suggesting it will not alter
normal T-cell activation. Thus, PLX8394 may be an appropriate partner with immune-based
therapies such as CTLA-4 and PD-1/PDL-1 inhibitors (52).
With an increasing number of available therapies for the treatment of mutant BRAF
melanomas, identifying the best therapy for an individual patient is increasingly important.
Patient-derived tumor xenograft (PDX) models accurately reproduce a patient’s response to
therapy (53); however, these models are associated with long generation times and high cost.
As an alternative, we describe a patient derived explant system, PDeX, to test multiple
treatment strategies using a single patient biopsy that accounts for intratumoral
heterogeneity by assaying multiple sample pieces from different parts of the lesion. The
ability of PDeX to test the efficacy of small molecule inhibitors and monoclonal antibodies
in a short time period offers an inexpensive and rapid assay that is individualized and may
inform patient treatment options.

Author Manuscript

As with other targeted therapies, acquired resistance to PLX8394 eventually occurs in our
pre-clinical studies. Phospho-proteomic analysis implicated well-known BRAF inhibitor
resistance markers in the PLX8394-resistant cell lines (40,43,54). However, initial
experiments suggest that enhanced AKT activity and up-regulation of PDGFR are not sole
drivers of resistance in these cells (Supplemental Figure 6). Rather, it is likely that they work
in co-ordination with re-activation of the ERK1/2 pathway. It is possible that resistance
mechanisms to PLX8394 will be unique from vemurafenib and dabrafenib and is
underscored by the finding that PBRT #16 is resistant to vertical targeting of the ERK1/2
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signaling pathway but is sensitive to BET/BRD inhibitor treatment. Since enrollment for
PLX8394 phase 1/2a study (ClinicalTrials.gov #NCT02428712) has only recently started,
resistance mechanisms in patients remain unknown.

Author Manuscript

In summary, PLX8394 is a promising next-generation mutant BRAF selective inhibitor that
does not elicit strong paradoxical ERK1/2 activation in non-mutant BRAF cells. PLX8394
monotherapy is entering clinical trials with hope that it will prevent side effects associated
with paradoxical ERK1/2 activation while simultaneously reducing grade 4 toxicities and
permanent discontinuations associated with dual inhibitor therapies (14). Our parallel dosing
experiments of tumor tissue suggest that PLX8394 is more effective than vemurafenib at
suppressing ERK1/2 signaling even when considering vemurafenib’s lower biochemical
potency (18). Additionally, the PDeX system utilized in this study provides a rapid and
quantitative method to determine the efficacy of PLX8394 (and other targeted therapies) in
patient tissues. As a result, our data suggest that PLX8394 is a promising new therapy for
the treatment of mutant BRAF melanomas refractive to vemurafenib, and that the PDeX
system can potentially be used to guide the treatment of patients in a personalized manner.
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Figure 1. PLX8394 effectively reduces ERK1/2 signaling and tumor volume in vivo
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A. 1205LuTR GAL4-ELK1 cells were treated for 24 hours with either DMSO or 0.5 μM
PLX8394. Lysates were obtained from three independent experiments and processed for
RPPA analysis. A heat map was generated using median-centered data across each protein
measurement for each sample. B. Proteins with a p value ≤ 0.01 and a fold change of ≥ 1.5
that were significantly altered following PLX8394 treatment. C. Mice bearing 1205LuTR
GAL4-ELK1 xenografts were fed either vehicle chow or PLX8394 laced chow.
Representative images of a vehicle and PLX8394 treated mouse with overlaid luciferase
output across 10 days of treatment are shown. D. Quantification of firefly luciferase. Graph
depicts fold change in luciferase output per tumor volume compared to vehicle for each day
of treatment. E. Average fold change in tumor volume between mice fed vehicle chow and
PLX8394-laced chow.
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Figure 2. PLX8394 effectively inhibits ERK1/2 signaling in patient tumors comparable to
dabrafenib/trametinib treatment

A. H&E and IHC analysis of pERK1/2 staining from a representative mutant BRAF patient
sample (TJU-MEL-27A) treated with either DMSO, vemurafenib (1 μM), combo (1 μM
dabrafenib/16 nM trametinib) or PLX8394 (0.5 μM). B. Quantitation of A across a panel of
6 different mutant BRAF melanoma patient samples. C. Western blot analysis of ERK1/2
signaling and PARP cleavage from a representative patient sample (TJU-MEL-27A). D.
Western blot quantitation of the normalized pERK1/2 to ERK2 signal from 5 patient
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samples. E. RPPA data from mutant BRAF patient samples were analyzed via GSEA.
Patient explants treated with vemurafenib (left) and PLX8394 (right), were grouped and
compared to DMSO treated samples. Enrichment of the Programmed Cell Death/Apoptosis
and Cell Cycle Arrest GO pathways and corresponding changes in RPPA determined protein
levels compared to DMSO are shown. Pathway nodes and protein levels for all treatments
are on the same scale (bottom left).
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Figure 3. PLX8394 suppresses MEK/ERK signaling in mutant BRAF splice variant expressing
cells and is associated with reduction of splice variant homodimerization

A. 1205LuTR GAL4-ELK1 cells were used to generate xenograft tumors that were
harvested and dissected into ~1 mm3 pieces for use in explant system. After 48 hours of
treatment, lysates were collected and analyzed by western blotting. Using densitometry, the
normalized ratio of phospho ERK1/2 to ERK2 levels and cleaved PARP to HSP90 for each
cohort was quantified and graphed. Data was analyzed with a two-way ANOVA corrected
for multiple comparisons with Tukey analysis. Error bars are +/− SEM, * p ≤ 0.05, ** p ≤
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0.01, *** p ≤ 0.001, **** p ≤ 0.0001. B. Similar to A except PRT#3 cell line was used to
generate xenograft tumors. C. Similar to A but PRT#4 xenograft tumors. D. Western blots of
whole cell lysates from 1205LuTR FLAG/Myc BRAF ΔEx 2-8 cells after 48 hours of
doxycycline induced splice variant expression and an additional 4 hours of PLX4720 or
PLX8394 treatment at the indicated concentration. E. Parallel lysates from D were used to
immunoprecipitate the FLAG tagged mutant BRAF splice variant and western blots reveal
its associated Myc tagged binding partner. F. Quantification of splice variant
homodimerization after treatment with 1 μM PLX4720 and 0.5 μM PLX8394 (N=4).
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Figure 4. PLX8394 prevents significant paradoxical ERK1/2 activation in WT BRAF melanomas

A. Western blot analysis of WT/WT melanoma cell lines after treatment with DMSO,
vemurafenib (1 μM), PLX8394 (0.5 μM) or trametinib (50 nM) for 48 hours. B. Quantitation
of the normalized pERK1/2 signal from A. C. As in Fig 2B, except that two different
WT/WT melanoma cells were used to form xenografts and were processed/treated in the ex
vivo explant system. Western blot analysis of lysates prepared from explants treated with
DMSO, vemurafenib or PLX8394 after 48 hours. Densitometry results of pERK1/2 to ERK2
are indicated. D. WT/WT patient sample explants (TJU-MEL-29) were treated as in A for 48
hours. Densitometry values are shown.
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Figure 5. In vivo acquired resistance of 1205LuTR GAL4-ELK1 xenografts to PLX8394

A. Progressing xenografts were harvested and used to generate PLX8394 resistant cell lines
(PBRTs). Crystal violet staining of PBRT #15 and #16 cells treated with increasing doses of
PLX8394 compared to parental cells is shown. B. Quantified results of three independent
experiments as in B. C. RPPA analysis of PBRT #15 and PBRT #16 cells compared to
parental cells treated with either DMSO or PLX8394 (0.5 μM) for 24 hours. Heatmap
showing proteins with a p value ≤ 0.01 and a fold change of ≥ 1.5 found to be significantly
altered in PBRT #15 or #16 cells when compared to parental cells.
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Figure 6. PBRTs have differential responses to second-line therapies
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A. 1205LuTR GAL4-ELK1, PBRT #15, and PBRT #16 were seeded in 6 well plates
overnight then cells were washed and media was replaced and supplemented with DMSO,
0.5 μM PLX8394, 1 μM vemurafenib, 50 nM trametinib, or 1 μM SCH772. After 24hours,
lysates were harvested and samples were analyzed by western blot. B. Quantification of
crystal violet 2D growth assays for 1205LuTR GAL4-ELK1, PBRT #15 and PBRT #16 in
the presence of increasing SCH772. Data points represent the average percent plate coverage
of at least three independent experiments. Error bars are SEM. C. S-phase entry of
1205LuTR GAL4-ELK1, PBRT #15 and PBRT #16 cells were assayed by EdU
incorporation. Graph is the average EdU positivity from at least three experimental
replicates. Error bars are SEM, * indicates p value < 0.05 compared to each cell line’s
DMSO condition using a two-way student’s T-test assuming unequal variance. D. Western
blot analysis of 1205LuTR GAL4-ELK1, PBRT #15 and PBRT #16 cells after 24 hour drug
treatment of DMSO, 0.5 μM PLX8394, or 1 μM JQ1. E–F. Similar to B-C except cells were
treated with JQ1.
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